Open App
Company / Corporate

Evofem Biosciences, Inc..

Follow Evofem Biosciences, Inc.

Company that acquired Lupin's rights and title to SOLOSEC (secnidazole), which was FDA-approved and marketed for sale to consumers as SOLOSEC.[1]

01Deal
01

Deals on Carrywatch

Every deal that names Evofem Biosciences, Inc., and its role in each.

Evofem Biosciences, Inc. / Lupin Inc.

Evofem Biosciences, Inc. agrees to buy Lupin Inc.

See deal details
02

Deal Web

Evofem Biosciences, Inc. and 0 firms it shares a posted deal with, and the path to any other firm.

03

Financials

6 fiscal years of figures as Evofem Biosciences, Inc. reported them.

04

News

Loading headlines.

05

Sources

As of 24 Oct 2026.

  1. 01
    Form 8-K, dated July 18, 2024

    U.S. Securities and Exchange Commission · Researched 24 Oct 2026

  2. 02
    SEC EDGAR company record for Evofem Biosciences, Inc.

    U.S. Securities and Exchange Commission · Researched 24 Oct 2026

Deal posts naming Evofem Biosciences, Inc.:

  1. P01